Marksans Pharma shares rally after its wholly owned subsidiary in UK received marketing authorisation for its product

Posted by on


Marksans Pharma Limited announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.

Comments

Post a Comment